This page uses content from Wikipedia and is licensed under CC BY-SA.


Clinical data
ATC code
  • None
CAS Number
PubChem CID
Chemical and physical data
Molar mass186.252 g·mol−1
3D model (JSmol)

Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype.[1][2] It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models,[3] and progressed as far as Phase II clinical trials for Parkinson's disease,[4] where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.


  1. ^ Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, et al. (March 2000). "Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist". Pharmaceutica Acta Helvetiae. 74 (2–3): 125–30. doi:10.1016/S0031-6865(99)00024-2. PMID 10812948.
  2. ^ Wagner FF, Comins DL (October 2006). "Expedient five-step synthesis of SIB-1508Y from natural nicotine". The Journal of Organic Chemistry. 71 (22): 8673–5. doi:10.1021/jo0616052. PMID 17064057.
  3. ^ Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND (October 2008). "Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist". Brain Research. 1234: 16–24. doi:10.1016/j.brainres.2008.07.063. PMID 18692487.
  4. ^ The Parkinson Study Group (February 2006). "Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease". Neurology. 66 (3): 408–10. doi:10.1212/01.wnl.0000196466.99381.5c. PMID 16476941.

Retrieved from "[]"